Lipid-Based Drug Carriers for Prodrugs to Enhance Drug Delivery

被引:0
作者
Jennica L. Zaro
机构
[1] University of Southern California,Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy
来源
The AAPS Journal | 2015年 / 17卷
关键词
drug delivery; fatty acids; glyceride; phospholipid; prodrug;
D O I
暂无
中图分类号
学科分类号
摘要
The combination of lipid drug delivery systems with prodrugs offers several advantages including improved pharmacokinetics, increased absorption, and facilitated targeting. Lipidization and use of lipid carriers can increase the pharmacological half-life of the drug, thus improving pharmacokinetics and allowing less frequent dosing. Lipids also offer advantages such as increased absorption through the intestines for oral drug absorption and to the CNS for brain delivery. Furthermore, the use of lipid delivery systems can enhance drug targeting. Endogenous proteins bind lipids in the blood and carry them to the liver to enable targeting of this organ. Drugs with significant side effects in the stomach can be specifically delivered to enterocytes by exploiting lipases for prodrug activation. Finally, lipids can be used to target the lymphatic system, thus bypassing the liver and avoiding first-pass metabolism. Lymphatic targeting is also important for antiviral drugs in the protection of B and T lymphocytes. In this review, both lipid-drug conjugates and lipid-based carriers will be discussed. An overview, including the chemistry and assembly of the systems, as well as examples from the clinic and in development, will be provided.
引用
收藏
页码:83 / 92
页数:9
相关论文
共 388 条
[61]  
Garzonaburbeh A(1989)The double prodrug concept and its applications Adv Drug Deliv Rev 3 39-65
[62]  
Poupaert JH(2013)Lipases, liposomes and lipid-prodrugs Curr. Opin. Colloid In 18 419-431
[63]  
Claesen M(2002)Tumor-directed targeting of liposomes Biosci Rep 22 267-281
[64]  
Dumont P(2014)Ligand-targeted liposome design: challenges and fundamental considerations Trends Biotechnol 32 32-45
[65]  
Atassi G(2001)Phototriggering of liposomal drug delivery systems Adv Drug Deliv Rev 53 273-284
[66]  
Garzonaburbeh A(2008)A review of stimuli-responsive nanocarriers for drug and gene delivery J Control Release 126 187-204
[67]  
Poupaert JH(2012)Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics Ther Deliv 3 599-608
[68]  
Claesen M(1994)Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells Bioconjug Chem 5 105-113
[69]  
Dumont P(1994)Flow cytometric evaluation of LDL receptors using DiI-LDL uptake and its application to B and T lymphocytic cell lines J Immunol Methods 177 55-67
[70]  
Lambert DM(2007)Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme J. Control. Release : offi J Controll Release Soc 124 163-171